MICHAEL LEVINSON: Open Payments
NPI 1306876883 · BURLINGAME, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,866 in 123 payments from 12 companies in 2025. Trend: 2023 $11,984 · 2024 $3,529 · 2025 $3,866
Food & beverage: $3,866
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 25 | $704 |
| E.R. Squibb & Sons, L.L.C. | 14 | $478 |
| Vanda Pharmaceuticals Inc. | 16 | $424 |
| Axsome Therapeutics, Inc. | 11 | $376 |
| Lundbeck LLC | 12 | $363 |
| Teva Pharmaceuticals USA, Inc. | 3 | $360 |
| Neurocrine BioSciences, Inc. | 12 | $336 |
| Alkermes, Inc. | 12 | $262 |
| Otsuka America Pharmaceutical, Inc. | 6 | $237 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $155 |
Products named: CAPLYTA, REXULTI, COBENFY, FANAPT, Auvelity, INGREZZA, ARISTADA, UZEDY.
Industry payments across CA — which companies pay providers there.
